The non‐amyloidogenic degradation pathway product of amyloid precursor protein (APP), known as sAPPα, exhibits a protective effect on AD pathophysiology by inhibiting GSK3β and reducing tau phosphorylation,136, 137 suggesting that other intermediate products of APP processing merit further attention in relation to their association with GSK3. The gene discussed is MAPT; the disease is Alzheimer disease.